Abstract | BACKGROUND: Obstructive sleep apnoea (OSA) causes intermittent hypoxia that in turn induces endothelial dysfunction and atherosclerosis progression. We hypothesised that VE-cadherin cleavage, detected by its released extracellular fragment solubilised in the blood (sVE), may be an early indicator of emergent abnormal endothelial permeability. Our aim was to assess VE-cadherin cleavage in OSA patients and in in vivo and in vitro intermittent hypoxia models to decipher the cellular mechanisms and consequences. METHODS: RESULTS: sVE was significantly elevated in sera from healthy volunteers submitted to intermittent hypoxia and OSA patients before treatment, but conversely decreased in OSA patients after 6 months of continuous positive airway pressure treatment. OSA was the main factor accounting for sVE variations in a multivariate analysis. In in vitro experiments, cleavage and expression of VE-cadherin increased upon HAEC exposure to intermittent hypoxia. TEER decreased and FITC-dextran flux increased. These effects were reversed by all of the pharmacological inhibitors tested. CONCLUSIONS:
|
Authors | Olfa Harki, Renaud Tamisier, Jean-Louis Pépin, Sébastien Bailly, Anissa Mahmani, Brigitte Gonthier, Aude Salomon, Isabelle Vilgrain, Gilles Faury, Anne Briançon-Marjollet |
Journal | The European respiratory journal
(Eur Respir J)
Vol. 58
Issue 4
(10 2021)
ISSN: 1399-3003 [Electronic] England |
PMID | 33737411
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright ©The authors 2021. For reproduction rights and permissions contact [email protected]. |
Chemical References |
- Antigens, CD
- Cadherins
- Vascular Endothelial Growth Factor A
- cadherin 5
|
Topics |
- Antigens, CD
- Cadherins
(metabolism)
- Capillary Permeability
- Endothelial Cells
(metabolism)
- Humans
- Hypoxia
- Permeability
- Sleep Apnea, Obstructive
- Vascular Endothelial Growth Factor A
|